Clinical trial · Interventional
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas
NCT00017446CI-TRIAL-00013318unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CP4071 in treating patients who have locally advanced or metastatic soft tissue sarcoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CP4071 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed soft tissue sarcoma * Metastatic or locally advanced * Failed at least 1 prior therapy * Measurable disease outside prior irradiation field * No CNS metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 2 times upper limit of normal (ULN) Renal: * Creatinine less than 1.5 times ULN * Calcium less than ULN * Potassium normal Other: * No other malignancy within the past 5 years except stage I or II cancer in complete remission, carcinoma in situ of the cervix, or basal cell or squamous cell skin cancer * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior biologic response modifier therapy allowed Chemotherapy: * No more than 3 prior chemotherapy regimens for advanced, recurrent, or metastatic disease * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy for malignancy Radiotherapy: * See Disease Characteristics * At least 3 weeks since prior radiotherapy and recovered * No concurrent radiotherapy Surgery: * At least 4 weeks since prior surgery and recovered Other: * No other concurrent cardiac glycosides
References
Publications (0)
Data not yet available
No reference posted for this study.